57 results about "Clinical tests" patented technology

A computer-implemented method of predicting, simulating, or forecasting values of one or more specified subject-related attributes during a clinical trial comprises: receiving input data comprising: a medical history of a subject, the medical history comprising values of a plurality of subject-related attributes of a subject; and data specifying a requested output, the data comprising: the one or more specified subject-related attributes of the subject and a time frame; and applying a trained generative machine-learning model to the received input data, the trained generative machine-learning model configured to generate output data based on the input data, the output data comprising: respective values of the one or more specified subject-related attributes of the subject in the specified time frame.

The present invention relates to a blood test method based on electrochemical impedance spectroscopy that can calculate clinical indicators in real time without separate clinical test equipment for calculating clinical indicators by changing the initial values ​​of blood parameters to fit the actual impedance and virtual impedance of the blood, and calculating clinical indicators using the blood parameters with changed initial values.

In some embodiments, the disclosed subject matter relates to systems and methods for designing and conducting clinical trials and biomarker validation studies. An example method includes: obtaining access to a trained computer-implemented model; providing, to the trained computer-implemented model, a plurality of sets of values for a plurality of features, each set of values corresponding to a candidate individual from a set of candidate individuals; receiving, from the trained computer-implemented model, a prediction of a disease state for each set of values; identifying a group of participants from the set of candidate individuals based on the prediction of the disease state; and facilitating at least one of a clinical trial or a biomarker validation study involving the group of participants.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine compound for treating pulmonary fibrosis of diabetes and application thereof. The traditional Chinese medicine compound comprises 70-90 parts of Huangqi, 20-40 parts of Danshen, 10-30 parts of Chuanxiong, 20-40 parts of Beishashen and 40-60 parts of Shanyao. The application also discloses application of the traditional Chinese medicine compound in preparation of a medicine for treating pulmonary fibrosis of diabetes of the type of deficiency of both qi and yin and blood stasis. The traditional Chinese medicine compound has reasonable formula, and uses the traditional Chinese medicine theory scientifically. The raw materials are matched according to the principle of monarch, minister, assistant and guide, and the traditional Chinese medicines are synergistically used, so that the traditional Chinese medicine compound can not only supplement deficiency of both qi and yin of diabetes, but also dredge stasis of collaterals of long-term disease, and achieve good clinical test effect by considering both the symptoms and the root cause.

The present application relates to a kind of HER2 gene and FGFR2 gene fluorescence in situ hybridization combined detection probe and its application, belong to biological medicine technical field.The present application provides a kind of probe and probe composition for tumor diagnosis and prognosis evaluation, including the first probe for detecting HER2 gene, and the second probe and the third probe for detecting FGFR2 gene;First probe, second probe and third probe are respectively marked with the first fluorochrome, second fluorochrome and third fluorochrome that can produce different colors;By the present application, a kind of fluorescence in situ hybridization combined detection method and its kit for simultaneously detecting HER2 and FGFR2 gene variation are provided;Wide application range can be used in various tissue and cell samples needing simultaneously detecting HER2 and FGFR2 gene state, one detection, two results, meet the goal of clinical test quality improvement and efficiency improvement;It has quite extensive application prospect.

The system provides a mechanism that allows both clinical trial participants and the managing organizations to work efficiently with simple processes throughout the entire clinical trial flow, and to ensure that each clinical trial process is performed reliably for the same participant. [Solution] The clinical trial support system 1 includes: an application input reception unit 2 that receives input of applications to participate in a clinical trial; a clinical trial process start recording unit 3 that, at the start of each clinical trial process in the clinical trial, identifies the clinical trial participant using terminal acquisition data obtained from the clinical trial participant's user terminal, accepts input of identity document data, and records clinical trial process start data indicating the start of the relevant clinical trial process if the identity is authenticated based on the identity document data; and a clinical trial process end recording unit 4 that, at the end of each clinical trial process, identifies the clinical trial participant using terminal acquisition data and records clinical trial process end data indicating the end of the relevant clinical trial process.

The application discloses an injection containing a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method of the injection. The preparation method of the injection is simple, the quality of the injection is stable, the injection is convenient for clinical administration, and the injection meets the requirements of subsequent clinical tests.

The present invention pertains to the anti-inflammatory therapeutic effect of xantohumol in spinal cord injury (SCI). The continuous administration of xanthohumol for 1-8 weeks to SCI rats resulted in improved results in 4 clinical tests used and in lowering and faster elimination of macrophages from the SCI lesion. Since the infiltration of the SCI lesion by numerous phagocytic macrophages indicates a severe destructive inflammation of extraordinary longevity, administration of xanthohumol is neuroprotective and resulted in a better and faster recovery of the locomotor function and the strength and sensory function in the hind limbs, in a shorter period of paralysis of the urinary bladder and in the recovery of the body weight lost due to the SCI surgery. Since the traumatic brain injury (TBI) involving the white matter, and stroke involving the white matter initiate the severe destructive inflammation as in the SCI, the administration of xanthohumol is expected to be anti-inflammatory and neuroprotective in both brain diseases. Since neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia and Parkinson's disease, immune mediated neuroinflammation including multiple sclerosis and neuromyelitis optica and cerebrospinal infections have inflammatory pathogenesis involving microgliosis and infiltration by macrophages, the administration of xanthohumol is expected to result in therapeutic inhibition of progression of all above diseases as well as of related neurodegenerative, immune mediated and infectious diseases of the brain and of the spinal cord.

Biomarkers for treatment response and other outcomes in the treatment of lesions, such as cancerous tumors, are derived from routine clinical medical images, such as computed tomography (CT) and magnetic resonance imaging (MRI) scans, using radiomic machine learning techniques. The biomarkers are based, at least in part, on phenotypes derived from vessel morphology features descriptive of vasculature associated with a lesion shown in the medical images and may also include other radiomic and pathomic types of features. The biomarkers and phenotypes may be used at multiple points in the treatment process, and treatment decisions may be based on changes in radiomic features or phenotypes longitudinally through the course of treatment. The biomarkers and phenotypes may also be used in clinical trials, to establish trial parameters, patient enrollment, drug dosage, and other trial parameters.

A method includes ingesting, by a clinical trial management platform, data from multiple clinical trial site systems associated with multiple clinical trials, responsive to authentication of user credentials of a user, providing the user with access to the clinical trial management platform, based on the user credentials, identifying a particular clinical trial associated with the user, through the clinical trial management platform, providing the user with access to multiple clinical trial software services based on the authenticated user credentials, based on the ingested data for the particular clinical trial associated with the user, presenting to the user a user-specific task list for user tasks related to the particular clinical trial; and through the clinical trial management platform, establishing a communication link between the user and another user, the communication link enabling direct, real-time messaging via the clinical trial management platform between the user and the other user.

The present application belongs to the technical field of radial artery compression hemostasis device, and particularly relates to a radial artery hemostasis method based on real-time pulse analysis and a hemostasis device control system. A slow and continuously changing force is applied to the radial artery puncture port by a pressure application module, while a pulse detection module transmits the forced feedback signal of the pulse at the puncture port to a master control module in real time. The master control module analyzes and processes the received feedback signal in real time and determines the current hemostasis state of the radial artery. Based on this, the pressure application module is controlled to adjust the pressure. The innovation of the present application lies in that the difference in the pulse feedback signal of the radial artery under different compression states is utilized, the relationship between the forced feedback signal of the pulse and the forced state of the radial artery is obtained through clinical trials, and the pressure is stabilized at a state where the radial artery blood flow is stable and the puncture port does not bleed. This scheme can overcome the individual differences between different patients and adaptively adjust the compression hemostasis force, thereby effectively reducing the incidence of radial artery occlusion and other related complications.

The present invention relates to a method for causing the preparation of a set of Quality Control, QC, sample containers, wherein each QC sample container comprises a QC material for controlling the quality of at least a clinical test of a laboratory analyzer. The method comprises: obtaining, by a computing device, QC data comprising information specifying a set of QC sample containers to be prepared and, for each QC sample container of the set of QC sample containers, a respective volume of the QC material to be included in said each QC sample container; and causing at least a portion of a primary volume of QC material included in a primary QC sample container to be aliquoted, based on the QC data, into the QC sample containers of the set of QC sample containers.

The application discloses a kind of external use traditional Chinese medicine preparation for treating cold blood stasis type granulomatous lobular mastitis and preparation method, and external use traditional Chinese medicine preparation is made of the raw materials including the following medicinal materials: prepared rhizome of rehmannia, antler slice, cassia, gunpowder ginger, chuanxiong, safflower, golden cypress, radix angelicae pubescentis, spironolactone, white and so on.The external preparation formula of the application is warm and blood tonic, blood-activating and skin-regenerating, has better clinical effect of treating cold blood stasis type granulomatous lobular mastitis, can effectively reduce the size of mass in clinical test, improve patient life treatment score, reduce the pain of patient, and has greater popularization and application value.

The present application relates to the technical field of data processing, and particularly relates to a clinical subject grouping processing method and system based on state detection. The method comprises the following steps: acquiring a multi-dimensional state detection data sequence of a target subject within a preset time window and performing time sequence alignment and cleaning; extracting a comprehensive physiological detection value by using a state feature extraction network, and then calculating a time sequence deterioration rate index and an expected steady state offset; based on the expected steady state offset, obtaining an imbalance deterioration degree of the target subject assigned to each candidate test group, and combining a risk assessment index of the target subject to obtain a final assignment probability score, and grouping the target subject based on the final assignment probability score. The present application can capture the implicit disease evolution trend of the subject, effectively intercept improper assignment actions, and guarantee the rationality and balance of the clinical trial grouping process.

The present application relates to a kind of C-MET gene and EGFR gene fluorescence in situ hybridization combined detection probe and its application, belong to biological medicine technical field.The present application provides a kind of probe and probe composition for tumor diagnosis and prognosis evaluation, including the first probe for detecting C-MET gene, and the second probe for detecting EGFR gene, the first probe and the second probe are labeled with the first fluorescein and the second fluorescein that can produce different colors respectively;By the present application, a kind of fluorescence in situ hybridization combined detection method and its kit for simultaneously detecting C-MET gene and EGFR gene gene variation are provided;Wide application range can be used in various tissue and cell samples needing simultaneously detecting C-MET gene and EGFR gene state, multiple results are detected once, meet the goal of clinical test quality improvement and efficiency improvement;It has quite extensive application prospect in the prognosis of various cancers.

The application discloses a kind of based on technical traceability clinical test result mutual recognition method, equipment and medium;Method includes the following steps: establishing traceability data management platform, and the clinical test result obtained by a plurality of different methodological detection is input into traceability data management platform;According to the clinical test result in traceability data management platform, establish standard test curve, simultaneously generate the mapping relationship of each methodological and standard test curve;Determine the risk value of each methodological to each traceability node;According to the determined risk value, new traceability node is formed and is recorded as label information in the corresponding clinical test result of traceability data management platform;Output clinical test result with traceability node.This application can effectively integrate the contribution value of various methodological, eliminate the bias generated by too much dependence on a method;At the same time, the detection process of other methodological is early warned, so that the clinical test result of other methodological can be expected.

The present application relates to a complex probiotic preparation containing Lactobacillus acidophilus WP285 and its use in the preparation of a product for inhibiting the formation of bird stone in pets, the strain in the complex probiotic preparation is composed of Bacillus coagulans Bacillus coagulans BC66 strain and Lactobacillus acidophilus Lactobacillus acidophilus WP285 strain. The present application finds that both BC66 strain and WP285 strain have excellent effect in inhibiting the formation of bird stone in pets, and they can synergistically enhance each other, the complex probiotic preparation can effectively reduce the pH value of the simulated stone formation environment and inhibit the formation and deposition of bird stone crystals in vitro; through pet clinical test, it is confirmed that the complex probiotic preparation can effectively and continuously adjust the urine pH value of susceptible cats to the weak acidic range which is not conducive to the formation of bird stone, and significantly reduces the number of bird stone crystals in urine.

The application discloses application of taraxasterol in targeted enhancement of DC tumor vaccines and belongs to the technical field of cellular immunity. The application provides application of taraxasterol (Tara) in preparation of a reagent for enhancing the targeting property and safety of a tumor vaccine based on dendritic cells (DCs), and the Tara-assisted DC tumor vaccine can improve the intervention and treatment effect of the DC tumor vaccine, improve the inflammatory reaction to the organism, improve the targeting property and safety of the DC tumor vaccine treatment, and provides a scientific and valuable implementation scheme for a clinical test stage of the DC tumor vaccine anti-tumor treatment, and has obvious application prospect.

The trial planning system of various embodiments herein may include a data warehouse configured to receive data from one or more data sources and interconnected with a modelling system and a forecasting system. Such a modelling system may include a pre-award module and a post-award module, each of which may comprise at least one model configured to generate a predictive trial output pertaining to the bid and planning phase and post-award phase of a clinical trial, respectively, including, without limitation, various metrics related to trial start-up, site activation, and patient recruitment. Such a forecasting system may include a variety of modules configured to enable a user to input various parameters relating to a trial, view and select sites for trial assessment, display various graphics details generated forecasts, and override the predictive trial outputs generated by the modelling system to develop more accurate, detailed, and granular forecasts for a given trial.

The present application relates to the technical field of biological diagnosis, and particularly relates to a mutant gene set for tumor molecular typing and application thereof, wherein the mutant gene set comprises 82 mutant genes including DNA methylation modification related genes, histone modification related genes, chromatin remodeling related genes, TCR signal pathway related genes, PI3K-AKT signal pathway related genes, JAK-STAT signal pathway related genes, immune escape related genes, P53 signal pathway related genes, tumor suppressor genes and NOTCH signal pathway related genes. The mutant gene set can be used for molecular typing, targeted therapy and overall survival prediction of intranodal peripheral T-cell lymphoma. The mutant gene set is verified by clinical trials, and is suitable for all primary and relapsed PTCL patients, relapsed or refractory peripheral T-cell lymphoma umbrella study based on genomics typing and PTCL patients receiving different treatment schemes, and has a very wide application range.

The trial planning system of various embodiments herein may include a data warehouse configured to receive data from one or more data sources and interconnected with a modelling system and a forecasting system. Such a modelling system may include a pre-award module and a post-award module, each of which may comprise at least one model configured to generate a predictive trial output pertaining to the bid and planning phase and post-award phase of a clinical trial, respectively, including, without limitation, various metrics related to trial start-up, site activation, and patient recruitment. Such a forecasting system may include a variety of modules configured to enable a user to input various parameters relating to a trial, view and select sites for trial assessment, display various graphics details generated forecasts, and override the predictive trial outputs generated by the modelling system to develop more accurate, detailed, and granular forecasts for a given trial.

The application discloses a liver cancer risk data processing method and system based on machine learning, comprising the following steps: acquiring a sample data set containing multi-dimensional clinical test indexes; screening a cross-algorithm consistency feature set through multi-algorithm cross-validation; constructing multiple machine learning models in parallel; evaluating and verifying the models by using a receiver operating characteristic curve, a calibration curve and a decision curve, and screening an optimal model; and verifying the prediction performance of the model on different data subsets. The data processing method adopted by the application has good classification performance and generalization ability by deeply mining data features through a machine learning algorithm based on conventional clinical test indexes.

This invention provides a method and system for predicting the recurrence risk of nasopharyngeal carcinoma (NPC) using multimodal data, belonging to the field of medical data processing technology. The method includes acquiring NPC data of different modalities, including whole-section pathological images, magnetic resonance imaging (MRI) images, and clinical test data; extracting features from the whole-section pathological images, MRI images, and clinical test data respectively; cascading the extracted features according to channels to achieve feature fusion; mapping the fused feature vectors to obtain NPC recurrence prediction probability data for different timeframes. This forms a unified decision-making path, providing data support for NPC recurrence prediction and facilitating the planning of subsequent treatment strategies.